CSTL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
103.5M
+23.7%
83.7M
-3.8%
87.0M
+4.8%
83.0M
-3.6%
86.2M
Cost of Revenue
23.7M
+15.4%
20.5M
+12.1%
18.3M
-2.1%
18.7M
+6.1%
17.6M
Gross Profit
79.8M
+26.4%
63.1M
-8.1%
68.7M
+6.8%
64.3M
-6.2%
68.6M
Operating Expenses
82.9M
+1.7%
81.6M
+12.5%
72.5M
+1.9%
71.1M
-2.3%
72.8M
R&D
14.5M
+0.8%
14.4M
+6.8%
13.5M
+4.3%
13.0M
+1.4%
12.8M
SG&A
66.1M
+1.9%
64.9M
+14.4%
56.7M
+1.5%
55.9M
-3.7%
58.1M
Operating Income
-3070000
+83.3%
-18407000
-381.0%
-3827000
+43.8%
-6804000
-60.1%
-4251000
EBITDA
1.0M
+106.9%
-14478000
-28856.0%
-50000
+98.3%
-2988000
-257.0%
-837000
Net Income
-2060000
+85.8%
-14522000
-522.7%
-2332000
-365.5%
-501000
-111.1%
4.5M
EPS (Basic)
$-0.07
+85.7%
$-0.49
-512.5%
$-0.08
-300.0%
$-0.02
-112.5%
$0.16
EPS (Diluted)
$-0.07
+85.7%
$-0.49
-512.5%
$-0.08
-300.0%
$-0.02
-113.3%
$0.15
Shares (Diluted)
30.4M
+1.7%
29.9M
+4.1%
28.7M
-1.2%
29.1M
-1.6%
29.5M
Castle Biosciences (CSTL) โ€” Financials